First-pass extracted concept

S1P receptor modulators

Candidate: concept label1 source documents5 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

sphingosine 1-phosphate receptor modulators

Extracted Explainers

What the tool is doing

S1P receptor modulators are described as drugs that target the S1P-S1P receptor axis in neurological, autoimmune, and inflammatory disorders. In MS, their main pharmacologic effect is induction of lymphopenia through loss of responsiveness to S1P gradients that guide lymphocyte egress.

Source 1DOI PubMed

What problem it solves

The review frames this class as a way to intervene in immune and nervous system pathophysiology relevant to multiple sclerosis. It also suggests these agents may address neuroinflammatory processes beyond peripheral lymphocyte trafficking.

Source 1DOI PubMed

What it does not solve

The abstract does not establish which specific disease settings beyond MS are clinically validated, nor does it resolve drug-by-drug differences within the class.

Source 1DOI PubMed

Alternatives

The supplied abstract does not name alternative non-S1P therapeutic classes for MS.

Source 1DOI PubMed

Evidence Snippets

The relevance of S1P-S1P receptor axis in the pathophysiology of immune and nervous systems has encouraged the development of S1P receptor modulators for the treatment of neurological, autoimmune and/or inflammatory disorders. Currently, four S1P receptor modulators are approved drugs for multiple sclerosis (MS).

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1review2021Pharmacology & TherapeuticsDOI PubMed

1 evidence snippet 5 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1cns targetingsupports2021Source 1DOI PubMed

S1P receptor modulators may cross the blood-brain barrier and directly target CNS resident cells expressing S1P receptors.

Quoted textsource-backed

Further, these drugs may cross the blood-brain barrier and directly target CNS resident cells expressing S1P receptors.

Claim 2mechanism of actionsupports2021Source 1DOI PubMed

The main pharmacologic effect of S1P receptor modulators in MS is induction of lymphopenia by causing loss of responsiveness to S1P gradients that guide lymphocyte egress from lymphoid organs into the bloodstream.

Quoted textsource-backed

As main pharmacologic effect, these treatments induce lymphopenia due to the loss of responsiveness to S1P gradients guiding lymphocyte egress from lymphoid organs into the bloodstream.

Claim 3mechanistic scopesupports2021Source 1DOI PubMed

S1P modulators have immunological effects beyond inhibition of lymphocyte trafficking.

Quoted textsource-backed

Recent data point to immunological effects of the S1P modulators beyond the inhibition of lymphocyte trafficking.

Claim 4therapeutic class statussupports2021Source 1DOI PubMed

Four S1P receptor modulators are approved drugs for multiple sclerosis.

Quoted textsource-backed

Currently, four S1P receptor modulators are approved drugs for multiple sclerosis (MS)

Claim 5translational implicationsupports2021Source 1DOI PubMed

Mechanistic insights from S1P receptor modulators in MS may help direct therapeutic approaches targeting S1P receptors in other disease areas.

Quoted textsource-backed

These insights can direct the application of therapeutic approaches targeting S1P receptors in other disease areas.